‘Inconsistent dosing, limited safety data, and minimal post-market surveillance’: the cannabis question

Pharmacists slam “aggressive” services offering medicinal cannabis, following the commencement of a probe into the sector The Pharmaceutical Society of Australia has taken aim at the way “loopholes” in the Special Access Scheme (SAS) and Authorised Prescriber (AP) schemes are being exploited in providing access to medicinal cannabis, increasing the risk of harm to the